Displaying drugs 4676 - 4700 of 5128 in total
Encaleret
Investigational
Gold
A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Experimental
TOL-101
Investigational
Tarafenacin
Investigational
CYT997
CYT997 is an orally available vascular argeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias.
Investigational
Revumenib
Investigational
Flavin-N7 protonated-adenine dinucleotide
Experimental
[2(Formyl-Hydroxy-Amino)-Ethyl]-Phosphonic Acid
Experimental
3-fluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzamide
Experimental
Nafamostat
Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing...
Investigational
Tamatinib
Experimental
Investigational
Anlotinib
Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
Investigational
ONCOSā102
Investigational
Cemdomespib
Cemdomespib is under investigation in clinical trial NCT05895552 (A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS)).
Investigational
Ethyl loflazepate
Experimental
Illicit
Dezapelisib
Dezapelisib is under investigation in clinical trial NCT02456675 (INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/refractory Hodgkin Lymphoma).
Investigational
Empegfilgrastim
Empegfilgrastim is under investigation in clinical trial NCT01569087 (Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer).
Investigational
Arimoclomol
Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
Investigational
Sebetralstat
Investigational
Tirabrutinib
Tirabrutinib is under investigation in clinical trial NCT02626026 (Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)).
Investigational
Allogeneic natural killer cells
Investigational
TBI-223
TBI-223 is under investigation in clinical trial NCT06192160 (Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis).
Investigational
Displaying drugs 4676 - 4700 of 5128 in total